the response rate favored nivolumab 32 versus 11 with lower grades 3 and 4 tox- icity 8 for nivolumab versus 31 for chemotherapy.table 1 fda-approved pd-1 and pd-l1 antibodies in canceragentindicationsettingdoseschedulestudy phase andsettingnkey outcomes by primary end pointnivolumabclassical hodgkinlymphomarelapsedrefractory 3 mgkg q2 weeksstem cell transplantrefractory phase ii tory phase iii vs chemotherapy 23 orr 87 17 crfor dacarbazine chemotherapymetastatic melanomafirst line1 mgkg q3 weeks incombination with ipilimumab for 4 doses then 3 mgkg q2 weeksfirst-line phase iii ipilimumab vs nivolumab vs combi- nation 945 11.5 months median pfs for ipinivo vs2.9 months for ipi vs6.9 months for nivometastatic nsclcrelapsedrefractory 3 mgkg q2 weeksnon-squamousnsclc phase iii vs docetaxel squamous nsclc phase iii vs doc- etaxel clear cell rccrelapsedrefractory 3 mgkg q2 weeksanti-vegfr refrac-tory phase iii vs everolimus pembrolizumab metastatic melanomafirst line2 mgkg q3weeksphase iii vs ipili-mumab tory phase i phase iii pem 2 vs 10 mgkg vs doc- etaxel hn sccrelapsedrefractory 200 mg q3weeksplatinum-refractoryrelapsed phase i atezolizumaburothelial cancerrelapsedrefractory 1200 mg iv q3 weeks platinum-refractoryrelapsed phase ii metastatic nsclcrelapsedrefractory 1200 mg iv q3 weeks platinum-refractoryrelapsed randomized phase iiivs docetaxel582 12.2 months median os vs 9.4 months for docetaxel272 9.2 months median os vs 6.0 months for docetaxel821 25.0 median os vs 19.6 months for everolimus834 pfs hr 0.58 vs ipios hr 0.69 for pem q3w vs ipi2 mgkg vs docetaxel and os hr 0.61 for pem 10 mgkg vs docetaxel174 16 orr310 15 orr144 13.8 months mos for atezo hr 0.73hn head and neck hr hazard ratio ipi ipilimumab nivo nivolumab nsclc non-small cell lung cancer os overall survival pfs progres- sion-free survival rcc renal cell carcinoma scc squamous cell carcinoma vegf r vascular endothelial growth factorpatients with braf mutant melanoma did as well as those with wild-type tumors in the phase ii and iii studies .

j clin oncol 32101020-1030. doirobert c long gv brady b dutriaux c maio m mortier l hassel jc rutkowski p mcneil c kalinka-warzocha e savage kj hernberg mm lebbe c charles j mihalcioiu c chiarion- sileni v mauch c cognetti f arance a schmidt h schaden- dorf d gogas h lundgren-eriksson l horak c sharkey b waxman im atkinson v ascierto pa 2015 nivolumab in pre- viously untreated melanoma without braf mutation.

can- cer discov 68827-837. doipeng w chen jq liu c malu s creasy c tetzlaff mt xu c mckenzie ja zhang c liang x williams lj deng w chen g mbofung r lazar aj torres-cabala ca cooper za chen pl tieu tn spranger s yu x bernatchez c for- get ma haymaker c amaria r mcquade jl glitza ic cas- cone t li hs kwong ln heffernan tp hu j bassett rl jr. bosenberg mw woodman se overwijk ww lizee g roszik j gajewski tf wargo ja gershenwald je radvanyi l davies ma hwu p 2016 loss of pten promotes resistance to t cell-mediated immunotherapy.

lancet oncol 177943-955. doihodi fs pm chesney ja pavlick ac robert c grossmann kf mcdermott df linette gp meyer n giguere jk agarwala s shaheen mf ernstoff ms minor dr salama ak taylor mh ott pa jiang j gagnier p wolchok jd 2016 overall survival in patients with advanced melanoma mel who discontinued treatment with nivolumab nivo plus ipilimumab ipi due to toxicity in a phase ii trial checkmate 069. in asco annual meeting chicago il 2016. j clin oncol vol 34 suppl abstr 9518hodi fs kh sznol m carvajal r lawrence d atkins m pow- derly j sharfman w puzanov i smith d leming p lipson e taube j anders r horak c jiang j mcdermott d sosman j brahmer j pardoll d topalian s 2016 durable long-term survival in previously treated patients with advanced melanoma mel who received nivolumab nivo monotherapy in a phase i trial in 107th annual meeting of the american association for cancer research new orleans la april 16-20 2016robert c ra hamid o daud a wolchok jd joshua am hwu w-j weber js gangadhar tc joseph rj dronca rs patnaik a zarour hm kefford r hersey p li x diede sj ebbing- haus s hodi fs 2016 three-year overall survival for patients with advanced melanoma treated with pembrolizumab in key- note-001.

in the current review we will briefly summarize the scientific background data supporting the development of pd-1pd-l1 blockade and then describe the track record of these antibodies in multiple different histologies ranging from melanoma andlung cancer to less common tumor types as well as discuss biomarkers that may assist in patient selection.keywords pd-1  pd-l1  immunotherapy  checkpoint inhibitors  biomarkers  microbiomeabbreviationsaacramerican association of cancer research ascoamerican society of clinical oncology bcgbacillus calmette-guerinciconfidence intervalcrcomplete responsectla-4cytotoxic t-lymphocyte associated protein-4 dcrdisease control rate orr and sdfksi-drsfunctional assessment of cancer therapy- kidney symptom index-disease-related symptomsgvhdgraft-versus-host diseasehcthematopoietic stem cell transplant hlhodgkin's lymphomaicimmune cellido1indoleamine 23 dioxygenase 1 ihcimmunohistochemistrymrdmismatch repair deficiency orrobjective response ratepcrpolymerase chain reactionpd-1programmed death-1pd-l1programmed death ligand-1 pd-l2programmed death ligand-2 ptenphosphatase and tensin homolog jeffrey s. weber 1 laura and isaac perlmutter cancer center nyu langone medical center 522 first avenue 1310 smilow research building new york ny 10016 usasdstable diseaseintroductionpd-1 or programmed death-1 was first identified and cloned in 1992 as a gene transcriptionally induced upon programmed cell death in t cells .

j clin oncol 28111850-1855. doialexandrov lb nik-zainal s wedge dc aparicio sa behjati s biankin av bignell gr bolli n borg a borresen-dale al boyault s burkhardt b butler ap caldas c davies hr desmedt c eils r eyfjord je foekens ja greaves m hosoda f hutter b ilicic t imbeaud s imielinski m jager n jones dt jones d knappskog s kool m lakhani sr lopez-otin c martin s munshi nc nakamura h northcott pa pajic m papaemmanuil e paradiso a pearson jv puente xs raine k ramakrishna m richardson al richter j rosenstiel p schle- sner m schumacher tn span pn teague jw totoki y tutt an valdes-mas r van buuren mm van 't veer l vincent- salomon a waddell n yates lr australian pancreatic can- cer genome i consortium ibc consortium im-s pedbrain i zucman-rossi j futreal pa mcdermott u lichter p mey- erson m grimmond sm siebert r campo e shibata t pfis- ter sm campbell pj stratton mr 2013 signatures of muta- tional processes in human cancer.

in sitc annual meeting national harbor md november 9-13 2016de santis m bellmunt j mead g kerst jm leahy m maroto p gil t marreaud s daugaard g skoneczna i collette s lor- ent j de wit r sylvester r 2012 randomized phase iiiii trial assessing gemcitabinecarboplatin and methotrexatecarboplatin vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy eortc study 30986. j clin oncol 302191-199. doibalar a galsky m loriot y dawson n necchi a srinivas s joseph r vaishampayan u sridhar s quinn d drakaki a duran i rosenberg j powles th-c jh cui n mariathasan s thastrom a abidoye o bajorin d 2016 atezolizumab atezo as first-line 1l therapy in cisplatin-ineligible locally advanced metastatic urothelial carcinoma muc primary analysis of imvigor210 cohort 1. in asco annual meeting chicago il 2016. j clin oncol vol 34 2016 suppl abstr lba4500massard c gordon ms sharma s rafii s wainberg za luke jj curiel tj colon-otero g hamid o sanborn re o'donnell ph drakaki a kurland j rebelatto mc jin x blake-haskins ja gupta ak nh s 2016 safety and efficacy of durvalumab medi4736 a pd-l1 antibody in urothelial bladder cancer.

the response rate was superior with pembrolizumab every 2 weeks 33.7 and every 3 weeks 32.9 compared with ipili- mumab 11.9 p  0.001. survival was improved for either pembrolizumab regimen compared to ipilimumab hazard ratio for death for pembrolizumab every 2 weeks 0.63 p  0.0005 hazard ratio for pembrolizumab every 3 weeks 0.69 p  0.0036. the data from this initial phase iii trial led to the fda breakthrough status and subse- quent approval of pembrolizumab in october 2014 for patients with advanced melanoma.combination studies with the ctla-4 blocking anti-body ipilimumab and nivolumab were pursued in the checkmate-004 phase i checkmate-069 randomized phase ii and checkmate-067 randomized phase iii stud- ies -.

the dynamic and adapting nature of the immune system makes biomarker development challenging but also lends to its limitless potential to maintain pace with cancer evo- lution and lead to durable outcomes previously impossible with conventional cancer therapies.acknowledgements jeffrey s. weber has received honoraria from bristol myers squibb glaskosmithkline merck astra zeneca genentech and emd serono has equity in celldex cytomx and altor and has been named on a patent by moffitt cancer center for a biomarker for ipilimumab sensitivity.compliance with ethical standardsconflict of interest arjun vasant balar has received honoraria from merck genentech and astra zeneca and has received contracted re- search support from merck genentech and astra zeneca.referencesishida y agata y shibahara k honjo t 1992 induced expression of pd-1 a novel member of the immunoglobu- lin gene superfamily upon programmed cell death.

n engl j med 3732123-135. doigaron eb rizvi na hui r leighl n balmanoukian as eder jp patnaik a aggarwal c gubens m horn l carcereny e ahn mj felip e lee js hellmann md hamid o goldman jw soria jc dolled-filhart m rutledge rz zhang j lunc- eford jk rangwala r lubiniecki gm roach c emancipa- tor k gandhi l investigators k- 2015 pembrolizumab for the treatment of non-small-cell lung cancer.

science 3506257207-211. doirizvi na hellmann md snyder a kvistborg p makarov v havel jj lee w yuan j wong p ho ts miller ml rekhtman n moreira al ibrahim f bruggeman c gasmi b zappasodi r maeda y sander c garon eb merghoub t wolchok jd schumacher tn chan ta 2015 cancer immunology.

in asco annual meeting chicago il 2016klapper ja downey sg smith fo yang jc hughes ms kammula us sherry rm royal re steinberg sm rosenberg s 2008 high-dose interleukin-2 for the treatment of metastatic renal cell carcinoma a retrospective analysis of response and survival in patients treated in the surgery branch at the national cancer institute between 1986 and 2006. cancer 1132293- 301. doimotzer rj rini bi mcdermott df redman bg kuzel tm harrison mr vaishampayan un drabkin ha george s logan tf margolin ka plimack er lambert am waxman im ham- mers hj 2014 nivolumab for metastatic renal cell carcinoma results of a randomized phase ii trial.

lancet oncol 168908-918. doirobert c schachter j long gv arance a grob jj mortier l daud a carlino ms mcneil c lotem m larkin j lorigan p neyns b blank cu hamid o mateus c shapira-frommer r kosh m zhou h ibrahim n ebbinghaus s ribas a investiga- tors k- 2015 pembrolizumab versus ipilimumab in advanced melanoma.

in asco annual meeting chicago il 2016. vol j clin oncol 34 2016 suppl abstr 3005tumeh pc harview cl yearley jh shintaku ip taylor ej robert l chmielowski b spasic m henry g ciobanu v west an carmona m kivork c seja e cherry g gutierrez aj grogan tr mateus c tomasic g glaspy ja emerson ro robins h pierce rh elashoff da robert c ribas a 2014 pd-1 blockade induces responses by inhibiting adaptive immune resistance.

immu- nol rev 20731-41. doisnyder a makarov v merghoub t yuan j zaretsky jm desrichard a walsh la postow ma wong p ho ts holl- mann tj bruggeman c kannan k li y elipenahli c liu c harbison ct wang l ribas a wolchok jd chan ta 2014 genetic basis for clinical response to ctla-4 blockade in melanoma.

